secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2026-05-22T21:00:37+00:00
Accession:  0001493152-26-025062
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt
--------------------------------------------------------------------------------

- Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.
- Net loss $3.4M vs $3.1M; operating expenses flat at ~$3.56M.
- USPTO granted third patent for Arbli (losartan) extending exclusivity through 2041; REZENOPY got Orange Book patent.
- GPO agreements for REZENOPY covering 5,000+ institutions; sales force starts June 1, 2026.
- Secured $11M non-dilutive debt financing to support commercialization and R&D pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/0001493152-26-025062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer